The stream · Daily digest
The stream: Thursday, October 29, 2026
10 briefs from ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 7
-
Abbott initiates CROWN-MV pivotal trial for Cephea device
Abbott has started the CROWN-MV study, a prospective pivotal trial that will enroll up to 585 patients with symptomatic mitral valve disease in the U.S., Canada and Europe. The trial will evaluate the safety and effectiveness of the investigational Cephea Mitral Valve System, a catheter-based replacement option for patients not candidates for surgery or transcatheter repair.
Source: Company press release (PR Newswire), October 29, 2026
-
Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy
The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.
Source: ClinicalTrials.gov registry record, October 29, 2026
-
Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma
The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.
Source: ClinicalTrials.gov registry record, October 29, 2026
-
Jiangsu Simcere registers Phase II/III trial of SIM0811 in acute ischemic stroke
Planned enrollment is 1092 participants and the study is expected to start on November 30, 2026, with primary completion projected for June 30, 2029. Researchers will compare different doses of SIM0811 to a placebo in patients treated within 4.5 to 24 hours after last known well.
Source: ClinicalTrials.gov registry record, October 29, 2026
-
Alexion posts results of Phase 3 ARTEMIS ravulizumab trial
The company posted results for its Phase 3 ARTEMIS study, which enrolled 555 participants and was terminated after primary completion on October 7, 2025. The trial assessed a single dose of ravulizumab IV versus placebo in adult participants with CKD undergoing non-emergent cardiac surgery with cardiopulmonary bypass.
Source: ClinicalTrials.gov results record, October 29, 2026
-
Boehringer Ingelheim posts results of 1-yr Tiotropium/Salmeterol study in COPD
Results for the 220-participant, Phase 3, randomized, triple-masked study were posted on October 29, 2026. The study compared FDC tiotropium/salmeterol with single agents and assessed FEV1, dyspnoea, health status and exacerbations.
Source: ClinicalTrials.gov results record, October 29, 2026
-
Talazoparib plus enzalutamide versus placebo in metastatic APMR prostate cancer
The authors reported that 805 patients were enrolled in the TALAPRO-2 phase 3 trial, with 402 assigned to talazoparib plus enzalutamide and 403 to placebo plus enzalutamide. Median follow-up for radiographic progression-free survival was 24·9 months for the talazoparib group and 24·6 months for the placebo group.
Source: PubMed record of a Phase III journal article, October 28, 2026
Policy · 3
-
BioMarin enters exclusive worldwide license for investigational Fabry therapy
BioMarin will make an upfront payment of $70 million for HM15421/GC1134A and may receive up to $405 million in milestone payments. The company will assume sole responsibility for all subsequent clinical development, manufacturing and commercialization outside of Korea.
Source: Company press release (PR Newswire), October 29, 2026
-
Novavax earns $125 million milestone as Sanofi launches Phase 3 flu-COVID combo trial in Europe
The payment was triggered when the fifth patient was dosed on Oct. 29, 2026. The study evaluates safety and immunogenicity of Nuvaxovid combined with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults 60 and older.
Source: Company press release (PR Newswire), October 29, 2026
-
Veeva Summit showcases AI and data innovations advancing agentic commercial
Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will share strategies at the Veeva Commercial Summit, Europe, 18-19 November in Copenhagen. Attendees will hear how industry-specific AI is enabling sales, marketing, and medical teams to improve customer engagement, uncover valuable insights, and accelerate compliant content delivery.
Source: Company press release (PR Newswire), October 29, 2026